share_log

Piper Sandler Maintains Overweight on Fulgent Genetics, Lowers Price Target to $65

Benzinga Real-time News ·  Nov 14, 2022 06:48

Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Overweight and lowers the price target from $70 to $65.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment